Skip to main content

Advertisement

Articles

Page 1 of 4

  1. A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubici...

    Authors: Spyridon Gennatas, Florence Chamberlain, Thomas Carter, Susanna Slater, Elena Cojocaru, Beth Lambourn, Anna Stansfeld, Radha Todd, Mark Verrill, Nasim Ali, Robin L. Jones, Peter Simmonds, Nicola Keay, Heather McCarty, Sandra Strauss, Vassilios Karavasilis…

    Citation: Clinical Sarcoma Research 2020 10:9

    Content type: Research

    Published on:

  2. Lack of using a validated algorithm to select patients is a source of selection bias in oncology studies using administrative claims. The objective of this study to evaluate published algorithms to identify pa...

    Authors: Nicole Princic, Donna McMorrow, Philip Chan and Lisa Hess

    Citation: Clinical Sarcoma Research 2020 10:8

    Content type: Research

    Published on:

  3. Osteosarcoma is a very aggressive primary bone tumour, affecting mainly young populations. Most cases diagnosed have distant macro- and micro-metastases at the time of diagnosis. Surgical resection with neoadj...

    Authors: Argyris C. Hadjimichael, Athanasios F. Foukas, Olga D. Savvidou, Andreas F. Mavrogenis, Amanda K. Psyrri and Panayiotis J. Papagelopoulos

    Citation: Clinical Sarcoma Research 2020 10:7

    Content type: Review

    Published on:

  4. Soft tissue dedifferentiated leiomyosarcoma with heterologous osteosarcomatous component is an extremely rare entity described in only few cases in the literature.

    Authors: Raffaele Gaeta, Davide Matera, Francesco Muratori, Giuliana Roselli, Giacomo Baldi, Domenico Andrea Campanacci and Alessandro Franchi

    Citation: Clinical Sarcoma Research 2020 10:6

    Content type: Case Report

    Published on:

  5. Uterine adenosarcoma (UA) is an extremely rare sarcoma subtype. There has been limited evaluation of the immune microenvironment in these tumors. The objective of this study is to examine and describe the immu...

    Authors: Ali Mohammed Refaat Ali, Jen-Wei Tsai, Cheuk Hong Leung, Heather Lin, Vinod Ravi, Anthony P. Conley, Alexander J. Lazar, Wei-Lien Wang and Michael J. Nathenson

    Citation: Clinical Sarcoma Research 2020 10:5

    Content type: Research

    Published on:

  6. Well- and dedifferentiated liposarcoma (WD/DDLPS) are rare mesenchymal malignant tumors that account for 20% of all sarcomas in adults. The WD form is a low-grade malignancy with a favourable prognosis which m...

    Authors: Anastassia Serguienko, Peder Braadland, Leonardo A. Meza-Zepeda, Bodil Bjerkehagen and Ola Myklebost

    Citation: Clinical Sarcoma Research 2020 10:4

    Content type: Research

    Published on:

  7. Autologous dendritic cells (DC) loaded with tumor-associated antigens (TAAs) are a promising approach for anticancer immunotherapy. Polyantigen lysates appear to be an excellent source of TAAs for loading onto...

    Authors: Anna Danilova, Vsevolod Misyurin, Aleksei Novik, Dmitry Girdyuk, Natalia Avdonkina, Tatiana Nekhaeva, Natalia Emelyanova, Nino Pipia, Andrey Misyurin and Irina Baldueva

    Citation: Clinical Sarcoma Research 2020 10:3

    Content type: Research

    Published on:

  8. To report on our experience using a simple optional form to facilitate communication on late effects between the patients and the oncologists during outpatient follow-up and to detail on the spectrum of challe...

    Authors: Ivar Hompland, Lena Fauske, Geir Fagerjord Lorem and Øyvind S. Bruland

    Citation: Clinical Sarcoma Research 2020 10:2

    Content type: Research

    Published on:

  9. Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluat...

    Authors: Florence Chamberlain, Sheima Farag, Constance Williams-Sharkey, Cecilia Collingwood, Lucia Chen, Sonia Mansukhani, Bodil Engelmann, Omar Al-Muderis, Dharmisha Chauhan, Khin Thway, Cyril Fisher, Robin L. Jones, Spyridon Gennatas and Charlotte Benson

    Citation: Clinical Sarcoma Research 2020 10:1

    Content type: Research

    Published on:

  10. Sarcomas are a rare, heterogeneous group of tumors with variable tendencies for aggressive behavior. Molecular markers for prognosis are needed to risk stratify patients and identify those who might benefit fr...

    Authors: Nam Q. Bui, Joanna Przybyl, Sally E. Trabucco, Garrett Frampton, Trevor Hastie, Matt van de Rijn and Kristen N. Ganjoo

    Citation: Clinical Sarcoma Research 2019 9:12

    Content type: Research

    Published on:

  11. Sarcomatoid carcinoma, or carcinosarcoma, is a neoplasm that contains both sarcomatous and carcinomatous elements. It is an extremely rare cancer most often arising from visceral organs. Here we report the sev...

    Authors: Nicholas King, Keshav Kukreja, Albina Murzabdillaeva, Yasir Ali, Jason Willis, Abhishek Maiti, Hilary Ma and Joan Bull

    Citation: Clinical Sarcoma Research 2019 9:10

    Content type: Case Report

    Published on:

  12. Conventional chondrosarcomas are malignant cartilage tumors considered radioresistant. Nevertheless, retrospective series show a small but significant survival benefit for patients with locally advanced diseas...

    Authors: Yvonne de Jong, Martha Ingola, Inge H. Briaire-de Bruijn, Alwine B. Kruisselbrink, Sanne Venneker, Ieva Palubeckaite, Bram P. A. M. Heijs, Anne-Marie Cleton-Jansen, Rick L. M. Haas and Judith V. M. G. Bovée

    Citation: Clinical Sarcoma Research 2019 9:9

    Content type: Research

    Published on:

  13. Uncoupling protein 1 (UCP1) is a mitochondral protein transporter that uncouples electron transport from ATP production. UCP1 is highly expressed in brown adipose tissue (BAT), including hibernomas, but its ex...

    Authors: Jessica Malzahn, Afroditi Kastrenopoulou, Ioanna Papadimitriou-Olivgeri, Dionysios J. Papachristou, Jennifer M. Brown, Udo Oppermann and Nick A. Athanasou

    Citation: Clinical Sarcoma Research 2019 9:8

    Content type: Research

    Published on:

  14. The legends for Figs. 3 and 5 of the article [1] incorrectly refer to an “all others group”. The corrected legends should read:

    Authors: Jerry W. Call, Yu Wang, Denisse Montoya, Norman J. Scherzer and Michael C. Heinrich

    Citation: Clinical Sarcoma Research 2019 9:7

    Content type: Correction

    Published on:

    The original article was published in Clinical Sarcoma Research 2019 9:4

  15. This study aims to explore how patients with metastatic gastrointestinal stromal tumour (GIST) experience the adverse effects of treatment, as expressed by the individuals themselves.

    Authors: Lena Fauske, Ivar Hompland, Geir Lorem, Hilde Bondevik and Øyvind S. Bruland

    Citation: Clinical Sarcoma Research 2019 9:6

    Content type: Research

    Published on:

  16. The use of imatinib, sunitinib, and regorafenib has transformed the treatment of advanced GIST. Sunitinib and regorafenib improve progression free-survival in the second (2L) and third (3L) line, respectively,...

    Authors: Jerry W. Call, Yu Wang, Denisse Montoya, Norman J. Scherzer and Michael C. Heinrich

    Citation: Clinical Sarcoma Research 2019 9:4

    Content type: Research

    Published on:

    The Correction to this article has been published in Clinical Sarcoma Research 2019 9:7

  17. Activating mutations of the receptor tyrosine kinase KIT are early events in the development of most gastrointestinal stromal tumors (GISTs). Although GISTs generally remain dependent on oncogenic KIT during tumo...

    Authors: Michael C. Heinrich, Janice Patterson, Carol Beadling, Yuexiang Wang, Maria Debiec-Rychter, Barbara Dewaele, Christopher L. Corless, Anette Duensing, Chandrajit P. Raut, Brian Rubin, Tamas Ordog, Matt van de Rijn, Jerry Call, Thomas Mühlenberg, Jonathan A. Fletcher and Sebastian Bauer

    Citation: Clinical Sarcoma Research 2019 9:3

    Content type: Research

    Published on:

  18. Atypical fibroxanthomas (AFX) and pleomorphic dermal sarcomas (PDS) are lesions of the skin with overlapping histologic features and unspecific molecular traits. PDS behaves aggressive compared to AFX. Thus, a...

    Authors: Christian Koelsche, Damian Stichel, Klaus G. Griewank, Daniel Schrimpf, David E. Reuss, Melanie Bewerunge-Hudler, Christian Vokuhl, Winand N. M. Dinjens, Iver Petersen, Michel Mittelbronn, Adrian Cuevas-Bourdier, Rolf Buslei, Stefan M. Pfister, Uta Flucke, Gunhild Mechtersheimer, Thomas Mentzel…

    Citation: Clinical Sarcoma Research 2019 9:2

    Content type: Research

    Published on:

  19. Doxorubicin is one of the most active drugs available for the treatment of sarcoma. Pegylated-liposomal doxorubicin (PLD) is a formulation of doxorubicin in which the doxorubicin is encapsulated in liposomes c...

    Authors: Malvi Savani, Paari Murugan and Keith M. Skubitz

    Citation: Clinical Sarcoma Research 2019 9:1

    Content type: Case Report

    Published on:

  20. Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10–24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis.

    Authors: Johnathan R. Lex, Scott Evans, Jonathan D. Stevenson, Michael Parry, Lee M. Jeys and Robert J. Grimer

    Citation: Clinical Sarcoma Research 2018 8:23

    Content type: Research

    Published on:

  21. Relapsed and refractory sarcomas continue to have poor survival rates. The cancer stem cell (CSC) theory provides a tractable explanation for the observation that recurrences occur despite dramatic responses t...

    Authors: Matteo M. Trucco, Christian F. Meyer, Katherine A. Thornton, Preeti Shah, Allen R. Chen, Breelyn A. Wilky, Maria A. Carrera-Haro, Lillian C. Boyer, Margaret F. Ferreira, Umber Shafique, Jonathan D. Powell and David M. Loeb

    Citation: Clinical Sarcoma Research 2018 8:21

    Content type: Research

    Published on:

  22. Periostin is a matricellular protein that is expressed in bone and joint tissues. To determine the expression of periostin in primary bone tumours and to assess whether it plays a role in tumour progression, w...

    Authors: Jennifer M. Brown, Akiro Mantoku, Afsie Sabokbar, Udo Oppermann, A. Bass Hassan, Akiro Kudo and Nick Athanasou

    Citation: Clinical Sarcoma Research 2018 8:18

    Content type: Research

    Published on:

  23. We studied two cases of rare fibrous bone tumors, namely desmoplastic fibroma (DF) and low-grade central osteosarcoma (LGCOS) resembling desmoplastic fibroma (DF-like LGCOS). As the clinical presentation, imag...

    Authors: Wangzhao Song, Eva van den Berg, Thomas C. Kwee, Paul C. Jutte, Anne-Marie Cleton-Jansen, Judith V. M. G. Bovée and Albert J. Suurmeijer

    Citation: Clinical Sarcoma Research 2018 8:16

    Content type: Case Report

    Published on:

  24. This report summarizes the proceedings of the 4th European Bone Sarcoma Networking Meeting, held in London, England, on 21 June 2017. The meeting brought together scientific and clinical researchers and repres...

    Authors: Sandra J. Strauss, Jakob Anninga, Rubina Baglio, Daniel Baumhoer, Sam Behjati, Stefan Bielack, Kjetil Boye, Javier M. Broto, Anne-Marie Cleton-Jansen, Andrea Degasperi, Abigail Evans, Franca Fagioli, Marta Fiocco, Nathalie Gaspar, Dominique Heymann, Nadia Hindi…

    Citation: Clinical Sarcoma Research 2018 8:17

    Content type: Meeting Report

    Published on:

  25. Tenosynovial giant cell tumors (TGCTs) or giant cell tumors of tendon sheath are neoplasms that arise in the synovium. They can be categorized as nodular (localized) or diffuse type (D-TGCT). Historically, sur...

    Authors: Nicholas Giustini, Nicholas M. Bernthal, Susan V. Bukata and Arun S. Singh

    Citation: Clinical Sarcoma Research 2018 8:14

    Content type: Case report

    Published on:

  26. Induction chemotherapy by isolated limb perfusion (ILP) with melphalan and tumour necrosis factor-α is an effective strategy to facilitate limb-conserving surgery in locally advanced extremity sarcoma. In a co...

    Authors: Jens Jakob, Henry G. Smith, Michelle J. Wilkinson, Tim Pencavel, Aisha B. Miah, Joseph M. Thomas, Per-Ulf Tunn, Lothar R. Pilz, Dirk C. Strauss, Peter Hohenberger and Andrew J. Hayes

    Citation: Clinical Sarcoma Research 2018 8:12

    Content type: Research

    Published on:

  27. Kaposi’s sarcoma is a low-grade mesenchymal angioproliferative tumor, most commonly observed in immunocompromised individuals, such as HIV-infected patients. Iatrogenic Kaposi’s sarcoma occurs in patients unde...

    Authors: Emilien Billon, Anne-Marie Stoppa, Lena Mescam, Massimo Bocci, Audrey Monneur, Delphine Perrot and François Bertucci

    Citation: Clinical Sarcoma Research 2018 8:11

    Content type: Research

    Published on:

  28. Post-transplant smooth muscle tumors (PTSMTs) are rare mesenchymal neoplasms which occur after solid organ or haematopoietic stem cell transplantation. PTSMT typically consist of Epstein–Barr-virus (EBV)+ smoo...

    Authors: Kristin Teiken, Mark Kuehnel, Jan Rehkaemper, Hans Kreipe, Florian Laenger, Kais Hussein and Danny Jonigk

    Citation: Clinical Sarcoma Research 2018 8:10

    Content type: Research

    Published on:

  29. One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, con...

    Authors: M. Libertini, I. Mitra, W. T. A. van der Graaf, A. B. Miah, I. Judson, R. L. Jones, K. Thomas, E. Moskovic, Z. Szucs, C. Benson and C. Messiou

    Citation: Clinical Sarcoma Research 2018 8:13

    Content type: Research

    Published on:

  30. To describe patient and tumor characteristics, treatments, and survival among older adults in the United States with advanced soft-tissue sarcoma (STS), across and by categories of specifically defined histolo...

    Authors: Rohan C. Parikh, Maria Lorenzo, Lisa M. Hess, Sean D. Candrilli, Steven Nicol and James A. Kaye

    Citation: Clinical Sarcoma Research 2018 8:8

    Content type: Research

    Published on:

  31. Soft tissue sarcomas (STS) are often treated with pre-operative radiation (RT), with or without chemotherapy, followed by wide local excision. Prognosis for these patients involves an interplay of tumor and pa...

    Authors: Nicholas P. Gannon, David M. King and Manpreet Bedi

    Citation: Clinical Sarcoma Research 2018 8:7

    Content type: Research

    Published on:

  32. The use of 18F-FDG PET–CT (PET–CT) is widespread in many cancer types compared to sarcoma. We report a large retrospective audit of PET–CT in bone and soft tissue sarcoma with varied grade in a single multi-disci...

    Authors: Ruth E. Macpherson, Sarah Pratap, Helen Tyrrell, Mehrdad Khonsari, Shaun Wilson, Max Gibbons, Duncan Whitwell, Henk Giele, Paul Critchley, Lucy Cogswell, Sally Trent, Nick Athanasou, Kevin M. Bradley and A. Bassim Hassan

    Citation: Clinical Sarcoma Research 2018 8:9

    Content type: Research

    Published on:

  33. Two national clinical trial groups, United Kingdom Children’s Cancer and Leukaemia Group (CCLG) and the German Paediatric Oncology and Haematology Group (GPOH) together undertook a randomised trial, EICESS-92,...

    Authors: Jeremy Whelan, Allan Hackshaw, Anne McTiernan, Robert Grimer, David Spooner, Jessica Bate, Andreas Ranft, Michael Paulussen, Herbert Juergens, Alan Craft and Ian Lewis

    Citation: Clinical Sarcoma Research 2018 8:6

    Content type: Research

    Published on:

  34. Soft tissue and bone sarcoma represent a broad spectrum of different pathology and genetic variance. Current chemotherapy regimens are derived from randomised trials and represent empirical treatment. Chemosen...

    Authors: Nicholas Calvert, Jiansha Wu, Sophie Sneddon, Jennifer Woodhouse, Richard Carey-Smith, David Wood and Evan Ingley

    Citation: Clinical Sarcoma Research 2018 8:4

    Content type: Research

    Published on:

  35. Retroperitoneal sarcomas (RPS) should be surgically managed in specialized sarcoma centers. However, it is not clearly demonstrated if clinical outcome is more influenced by Center Case Volume (CCV) or by Surg...

    Authors: Sergio Sandrucci, Agostino Ponzetti, Claudio Gianotti, Baudolino Mussa, Patrizia Lista, Giovanni Grignani, Marinella Mistrangelo, Oscar Bertetto, Daniela Di Cuonzo and Giovannino Ciccone

    Citation: Clinical Sarcoma Research 2018 8:3

    Content type: Research

    Published on:

  36. Papillary intralymphatic angioendothelioma (PILA) is a locally aggressive, rarely metastasizing vascular tumor, generally occurring in the soft tissues, with less than 40 cases described in the literature and ...

    Authors: Marco Gambarotti, Alberto Righi, Marta Sbaraglia, Giuseppe Bianchi, Piero Picci, Daniel Vanel and Angelo Paolo Dei Tos

    Citation: Clinical Sarcoma Research 2018 8:1

    Content type: Case report

    Published on:

  37. Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the ...

    Authors: Salvatore Provenzano, Alessandra Raimondi, Rossella M. Bertulli, Vittoria Colia, Salvatore L. Renne, Paola Collini, Gianpaolo Dagrada, Dario Callegaro, Marco Fiore, Francesca G. Greco and Paolo G. Casali

    Citation: Clinical Sarcoma Research 2017 7:20

    Content type: Case report

    Published on:

  38. Treatment of giant cell tumour of bone (GCTB) of the distal radius/ulna poses a surgical challenge, as complex reconstructive surgery may be required. This study evaluates the clinical, radiological and pathol...

    Authors: Catherine L. McCarthy, Christopher L. M. H. Gibbons, Kevin M. Bradley, A. Bass Hassan, Henk Giele and Nicholas A. Athanasou

    Citation: Clinical Sarcoma Research 2017 7:19

    Content type: Research

    Published on:

  39. Since treatment patterns in metastatic soft tissue sarcoma (mSTS) have not been studied subsequent to US approval of pazopanib in 2012, this study sought to examine mSTS treatment patterns by line of therapy, ...

    Authors: Victor M. Villalobos, Stacey DaCosta Byfield, Sameer R. Ghate and Oluwakayode Adejoro

    Citation: Clinical Sarcoma Research 2017 7:18

    Content type: Research

    Published on:

  40. VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intracellular antigen termed cytoskeleton-linking membrane protein 63. rER is typically found in viable tumour cells and is ab...

    Authors: E. S. Hookway, Z. Orosz, Y. Uchihara, A. Grigoriadis, A. B. Hassan, U. Oppermann and N. A. Athanasou

    Citation: Clinical Sarcoma Research 2017 7:17

    Content type: Research

    Published on:

  41. We report on the activity of anthracycline-based and high-dose prolonged-infusion ifosfamide chemotherapy in a retrospective series of patients affected by advanced myxofibrosarcoma treated at Istituto Naziona...

    Authors: Vittoria Colia, Marco Fiore, Salvatore Provenzano, Elena Fumagalli, Rossella Bertulli, Carlo Morosi, Angelo P. Dei Tos, Marta Barisella, Alessandro Gronchi, Paolo G. Casali and Roberta Sanfilippo

    Citation: Clinical Sarcoma Research 2017 7:16

    Content type: Research

    Published on:

  42. Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case reports or...

    Authors: R. B. Cohen-Hallaleh, H. G. Smith, R. C. Smith, G. F. Stamp, O. Al-Muderis, K. Thway, A. Miah, K. Khabra, I. Judson, R. Jones, C. Benson and A. J. Hayes

    Citation: Clinical Sarcoma Research 2017 7:15

    Content type: Research

    Published on: